# LISRAYA
> **NDA220106** · New Drug Application · Sponsor: PRIOVANT THERAP · Approved 2026-08-27
## Drug
- **FDA Application Number:** NDA220106
- **Application type:** New Drug Application
- **Brand name:** LISRAYA
- **Generic name:** BREPOCITINIB
- **Active ingredients:** BREPOCITINIB TOSYLATE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** PRIOVANT THERAP
- **Manufacturer:** Priovant Therapeutics, Inc.
- **First approval:** 2026-08-27
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220106)
---
*MORVS · CC0 1.0*